Table 2.
Anthropometric, clinical, and biochemical parameters for placebo and resveratrol groups before and after resveratrol supplementation.
| Control/placebo group | Intervention/resveratrol group | |||||
|---|---|---|---|---|---|---|
| Baseline | After 45 days | P value | Baseline treatment | After treatment | P value | |
| Body weight (kg) | 76.60 ± 14.27 | 76.60 ± 14.16 | 0.809 | 74.26 ± 11.39 | 74.48 ± 11.34 | 0.712 |
| BMI (kg/m2) | 27.83 ± 4.21 | 27.69 ± 4.15 | 0.332 | 27.05 ± 3.13 | 27.16 ± 3.13 | 0.395 |
| Systolic blood pressure (mmHg) | 129.31 ± 15.16 | 130.68 ± 13.21 | 0.147 | 129.03 ± 14.91 | 121.45 ± 10.26 | <0.0001* |
| Diastolic blood pressure (mmHg) | 78.58 ± 15.39 | 81.55 ± 5.84 | 0.279 | 76.93 ± 19.54 | 78.54 ± 6.35 | 0.169 |
| Fasting glucose (mg/dL) | 151.24 ± 51.52 | 161.13 ± 53.16 | 0.002* | 175.74 ± 49.63 | 140.80 ± 39.74 | <0.0001* |
| Insulin (µIU/mL) | 9.04 ± 5.35 | 8.77 ± 4.16 | 0.642 | 10.20 ± 4.33 | 5.37 ± 2.62 | <0.0001* |
| HbA1c | 8.30 ± 1.43 | 8.50 ± 2.46 | 0.764 | 8.6 ± 1.390 | 7.60 ± 1.32 | <0.0001* |
| HOMA-IR | 3.20 ± 2.37 | 3.43 ± 1.83 | 0.423 | 4.61 ± 2.77 | 1.91 ± 1.17 | <0.0001* |
| HOMA-β | 36.13 ± 8.45 | 35.68 ± 7.95 | 0.039 | 32.15 ± 5.32 | 25.80 ± 4.43 | 0.009* |
| Triglyceride (mg/dL) | 134.69 ± 45.61 | 123.13 ± 43.27 | 0.145 | 160.1 ± 58.96 | 142.28 ± 52.61 | 0.051 |
| Total cholesterol (mg/dL) | 168 ± 41.97 | 175.34 ± 41.31 | 0.424 | 203.61 ± 52.70 | 192.28 ± 53.13 | 0.156 |
| HDL-cholesterol (mg/dL) | 41.73 ± 9.52 | 39.69 ± 10.83 | 0.133 | 41.40 ± 8.35 | 46.15 ± 8.40 | 0.001* |
| LDL-cholesterol (mg/dL) | 107.95 ± 31.67 | 117.18 ± 29.88 | 0.003* | 134.04 ± 36.18 | 122.71 ± 38.19 | 0.106 |
| SGOT (IU/L) | 24.0 ± 5.47 | 25.0 ± 6.71 | 0.212 | 26.0 ± 5.87 | 26.0 ± 7.56 | 0.837 |
| SGPT (IU/L) | 19.44 ± 8.79 | 21.65 ± 8.67 | 0.202 | 21.45 ± 7.91 | 22.61 ± 9.74 | 0.365 |
| GGT (IU/L) | 30.82 ± 17.79 | 29.93 ± 17.01 | 0.545 | 32.12 ± 15.32 | 33.38 ± 17.92 | 0.441 |
| ALP (IU/L) | 169.37 ± 52.63 | 189.41 ± 48.38 | 0.001* | 185.29 ± 59.35 | 190.64 ± 47.55 | 0.372 |
| Creatinine (mg/dL) | 0.92 ± 0.24 | 0.97 ± 0.25 | 0.281 | 0.96 ± 0.24 | 0.90 ± 0.21 | 0.098 |
Data is presented as means ± SD. *P < 0.05 versus before treatment. HOMA-β: homeostasis model of assessment for beta cell function; HOMA-IR: homeostasis model of assessment for insulin resistance; HbA1c: Hemoglobin A1c; HDL: high density lipoprotein; LDL: low density lipoprotein; TG: triglyceride; SGOT: serum glutamate oxaloacetate transaminase; SGPT: serum glutamate pyruvate transaminase; GGT: gamma-glutamyltransferase; ALP: alkaline phosphatase.